CureDuchenne Media Statement Regarding BioMarin's and Prosensa Holding N.V.'s Agreement on Intended Public Offer for 100% of Prosensaâs Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare Disease Portf